

# Melinta Therapeutics Inc - Strategic SWOT Analysis Review

<https://marketpublishers.com/r/M20CD7DDBE7EN.html>

Date: December 2021

Pages: 32

Price: US\$ 125.00 (Single User License)

ID: M20CD7DDBE7EN

## Abstracts

Melinta Therapeutics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

## Scope

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – GlobalData's summarization of the company's business strategy.

SWOT analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

## Highlights

Melinta Therapeutics Inc (Melinta) is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of various bacterial infections. Its marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin for the treatment of serious community-acquired bacterial pneumonia (CABP), meropenem and vaborbactam, oritavancin, and minocycline. Melinta's products and pipeline candidates are built on ribosome platform licensed from Yale University. Melinta is headquartered in New Haven, Connecticut, the US.

### Melinta Therapeutics Inc Key Recent Developments

Oct 25,2021: Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development

Jul 06,2021: Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy

Jun 29,2021: Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer

Mar 29,2021: Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer

Nov 16,2020: Melinta Therapeutics announces appointment of Kristen Allgor as Chief Human Resources Officer

## Reasons to Buy

Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.

Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.

Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

**Note:** Some sections may be missing if data is unavailable for the company.

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Melinta Therapeutics Inc - Key Facts  
Melinta Therapeutics Inc - Key Employees  
Melinta Therapeutics Inc - Key Employee Biographies  
Melinta Therapeutics Inc - Major Products and Services  
Melinta Therapeutics Inc - History  
Melinta Therapeutics Inc - Company Statement  
Melinta Therapeutics Inc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Melinta Therapeutics Inc - Business Description  
Melinta Therapeutics Inc - Corporate Strategy  
Melinta Therapeutics Inc - SWOT Analysis  
SWOT Analysis - Overview  
Melinta Therapeutics Inc - Strengths  
Melinta Therapeutics Inc - Weaknesses  
Melinta Therapeutics Inc - Opportunities  
Melinta Therapeutics Inc - Threats  
Melinta Therapeutics Inc - Key Competitors

### **SECTION 3 – COMPANY’S LIFESCENCES FINANCIAL DEALS AND ALLIANCES**

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Melinta Therapeutics Inc, Recent Deals Summary

### **SECTION 4 – COMPANY’S RECENT DEVELOPMENTS**

Oct 25, 2021: Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development

Jul 06, 2021: Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy

Jun 29, 2021: Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer

Mar 29, 2021: Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer

Nov 16, 2020: Melinta Therapeutics announces appointment of Kristen Allgor as Chief Human Resources Officer

Aug 03, 2020: Melinta Therapeutics announces appointment of Christine Ann Miller as President and Chief Executive Officer

Apr 20, 2020: Melinta Therapeutics successfully completes financial restructuring

Feb 13, 2020: Melinta Therapeutics announces court approval of chapter 11 bidding procedures

## **SECTION 5 – APPENDIX**

Methodology

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Melinta Therapeutics Inc, Key Facts

Melinta Therapeutics Inc, Key Employees

Melinta Therapeutics Inc, Key Employee Biographies

Melinta Therapeutics Inc, Major Products and Services

Melinta Therapeutics Inc, History

Melinta Therapeutics Inc, Subsidiaries

Melinta Therapeutics Inc, Key Competitors

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Melinta Therapeutics Inc, Recent Deals Summary

## List Of Figures

### LIST OF FIGURES

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD  
2021

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD  
2021

## I would like to order

Product name: Melinta Therapeutics Inc - Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/M20CD7DDBE7EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M20CD7DDBE7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970